Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595163406> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2595163406 endingPage "9025" @default.
- W2595163406 startingPage "9025" @default.
- W2595163406 abstract "9025 Background: Ipilimumab and tremelimumab are human monoclonal antibodies against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival with durable-long-term responses for advanced melanoma patients both in first-and second-line setting. Up to date, there is no proven association between the BRAF-V600E mutation and the disease control rate (DCR) in response to Ipilimumab. Moreover, significantly shorter survival rates have been reported in patients harboring an NRAS mutation than in those without. This retrospective analysis was carried out to assess if BRAF (V600) and NRAS mutation status affects the clinical outcome of Ipilimumab-treated melanoma patients. Methods: This is a retrospective multi-center analysisof 71 patients, with confirmed BRAF and NRAS mutation status, treated with anti-CTLA-4 antibodies from December 2006 until August 2012. The cut-off for the estimation of overall survival was end of November 2012. Results: The median overall survival of BRAFV600/NRAS mutant patients (n=44) was 1,41 years compared with 2.67 years in BRAF/NRAS wild-type patients (n=27). Although this difference was not statistically significant there was a trend for improved survival in wild-type patients. Of the 71 patients analyzed, 56 received chemotherapy prior to Ipilimumab. In the BRAF/NRAS mutant cohort, 12 patients received Ipilimumab following either a BRAF- or a MEK- inhibitor. Of those 12 patients, 8 progressed and were unable to complete Ipilimumab. Of the 4 patients who completed 4 cycles of Ipilimumab, 2 were subsequently treated with a BRAF inhibitor. Furthermore out of the 71 patients, 8 patients received a BRAF or a MEK inhibitor after progression; 5 of them are still alive. Conclusions: This is the first retrospective study to evaluate the association of both BRAF and NRAS mutational status with the overall survival of Ipilimumab-treated patients. There was a trend towards an improved survival in the BRAF/NRAS wild-type subpopulation. Additional patients will be examined to foster these preliminary results." @default.
- W2595163406 created "2017-03-23" @default.
- W2595163406 creator A5008000580 @default.
- W2595163406 creator A5015546743 @default.
- W2595163406 creator A5031190166 @default.
- W2595163406 creator A5031930763 @default.
- W2595163406 creator A5037399273 @default.
- W2595163406 creator A5038532092 @default.
- W2595163406 creator A5044736874 @default.
- W2595163406 creator A5049113366 @default.
- W2595163406 creator A5074293408 @default.
- W2595163406 creator A5076510325 @default.
- W2595163406 creator A5078577261 @default.
- W2595163406 creator A5082278497 @default.
- W2595163406 creator A5089297467 @default.
- W2595163406 date "2013-05-20" @default.
- W2595163406 modified "2023-09-27" @default.
- W2595163406 title "Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?" @default.
- W2595163406 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.9025" @default.
- W2595163406 hasPublicationYear "2013" @default.
- W2595163406 type Work @default.
- W2595163406 sameAs 2595163406 @default.
- W2595163406 citedByCount "3" @default.
- W2595163406 countsByYear W25951634062013 @default.
- W2595163406 countsByYear W25951634062014 @default.
- W2595163406 crossrefType "journal-article" @default.
- W2595163406 hasAuthorship W2595163406A5008000580 @default.
- W2595163406 hasAuthorship W2595163406A5015546743 @default.
- W2595163406 hasAuthorship W2595163406A5031190166 @default.
- W2595163406 hasAuthorship W2595163406A5031930763 @default.
- W2595163406 hasAuthorship W2595163406A5037399273 @default.
- W2595163406 hasAuthorship W2595163406A5038532092 @default.
- W2595163406 hasAuthorship W2595163406A5044736874 @default.
- W2595163406 hasAuthorship W2595163406A5049113366 @default.
- W2595163406 hasAuthorship W2595163406A5074293408 @default.
- W2595163406 hasAuthorship W2595163406A5076510325 @default.
- W2595163406 hasAuthorship W2595163406A5078577261 @default.
- W2595163406 hasAuthorship W2595163406A5082278497 @default.
- W2595163406 hasAuthorship W2595163406A5089297467 @default.
- W2595163406 hasBestOaLocation W25951634062 @default.
- W2595163406 hasConcept C121608353 @default.
- W2595163406 hasConcept C126322002 @default.
- W2595163406 hasConcept C143998085 @default.
- W2595163406 hasConcept C167135981 @default.
- W2595163406 hasConcept C203014093 @default.
- W2595163406 hasConcept C21705690 @default.
- W2595163406 hasConcept C21790070 @default.
- W2595163406 hasConcept C2776090121 @default.
- W2595163406 hasConcept C2777658100 @default.
- W2595163406 hasConcept C2777701055 @default.
- W2595163406 hasConcept C2781187634 @default.
- W2595163406 hasConcept C2781433595 @default.
- W2595163406 hasConcept C502942594 @default.
- W2595163406 hasConcept C526805850 @default.
- W2595163406 hasConcept C71924100 @default.
- W2595163406 hasConcept C8891405 @default.
- W2595163406 hasConceptScore W2595163406C121608353 @default.
- W2595163406 hasConceptScore W2595163406C126322002 @default.
- W2595163406 hasConceptScore W2595163406C143998085 @default.
- W2595163406 hasConceptScore W2595163406C167135981 @default.
- W2595163406 hasConceptScore W2595163406C203014093 @default.
- W2595163406 hasConceptScore W2595163406C21705690 @default.
- W2595163406 hasConceptScore W2595163406C21790070 @default.
- W2595163406 hasConceptScore W2595163406C2776090121 @default.
- W2595163406 hasConceptScore W2595163406C2777658100 @default.
- W2595163406 hasConceptScore W2595163406C2777701055 @default.
- W2595163406 hasConceptScore W2595163406C2781187634 @default.
- W2595163406 hasConceptScore W2595163406C2781433595 @default.
- W2595163406 hasConceptScore W2595163406C502942594 @default.
- W2595163406 hasConceptScore W2595163406C526805850 @default.
- W2595163406 hasConceptScore W2595163406C71924100 @default.
- W2595163406 hasConceptScore W2595163406C8891405 @default.
- W2595163406 hasIssue "15_suppl" @default.
- W2595163406 hasLocation W25951634061 @default.
- W2595163406 hasLocation W25951634062 @default.
- W2595163406 hasLocation W25951634063 @default.
- W2595163406 hasOpenAccess W2595163406 @default.
- W2595163406 hasPrimaryLocation W25951634061 @default.
- W2595163406 hasRelatedWork W1978192005 @default.
- W2595163406 hasRelatedWork W2046134042 @default.
- W2595163406 hasRelatedWork W2138562391 @default.
- W2595163406 hasRelatedWork W2513285370 @default.
- W2595163406 hasRelatedWork W2593804207 @default.
- W2595163406 hasRelatedWork W2618451551 @default.
- W2595163406 hasRelatedWork W2912374321 @default.
- W2595163406 hasRelatedWork W3172143226 @default.
- W2595163406 hasRelatedWork W4240190405 @default.
- W2595163406 hasRelatedWork W4309907129 @default.
- W2595163406 hasVolume "31" @default.
- W2595163406 isParatext "false" @default.
- W2595163406 isRetracted "false" @default.
- W2595163406 magId "2595163406" @default.
- W2595163406 workType "article" @default.